

24 December 2024

Completion of Genotype Risk Assessment Portfolio Acquisition

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**) advises that it has completed the acquisition of select Australian and US assets related to the Genotype Business from Genetic Technologies Ltd (**GTG**) (Administrators Appointed) (**GTG Administrators**).

Completion Details

As follow-up to the acquisition announcement to the market on 23 December 2024, Rhythm has paid the GTG Administrators and select trade creditors the required cash amounts and has assumed the statutory employee entitlements for transferring employees in Australia.

Rhythm CEO and Managing Director, Dr David Atkins said, “We are pleased to have the Genotype business in the RHY Group and we warmly welcome the employees both here and, in the US, and we look forward to working closely with them to accelerate development of the business within the combined company. To this end we have already commenced preliminary discussions on opportunities which can be leveraged immediately between the businesses and high-level integration planning.”

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

| | |
|---|---|
| David Atkins, PhD Managing Director Chief Executive Officer | Andrea Steele Joint Company Secretary & General Counsel |
|---|---|

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience’s simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia’s CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors

Otto Buttula
Sue MacLeman
Gavin Fox-Smith
David Atkins

Non-Executive Chairman
Non-Executive Director
Non-Executive Director
CEO & Managing Director